Log in to save to my catalogue

Phase III Study with FOLFIRI + Cetuximab Versus FOLFIRI + Cetuximab Followed by Cetuximab Alone in R...

Phase III Study with FOLFIRI + Cetuximab Versus FOLFIRI + Cetuximab Followed by Cetuximab Alone in R...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2275930470

Phase III Study with FOLFIRI + Cetuximab Versus FOLFIRI + Cetuximab Followed by Cetuximab Alone in RAS and BRAF WT mCRC

Publication information

Publisher

England: Future Medicine Ltd

More information

Scope and Contents

Contents

The optimal duration and intensity of first-line therapy in metastatic colorectal cancer patients once they have achieved an objective response is controversial. In a molecularly selected RAS and BRAF wild-type (wt) population, this concern is amplified. Once disease control has been achieved with a combination therapy including an anti-EGFR antibo...

Alternative Titles

Full title

Phase III Study with FOLFIRI + Cetuximab Versus FOLFIRI + Cetuximab Followed by Cetuximab Alone in RAS and BRAF WT mCRC

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2275930470

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2275930470

Other Identifiers

ISSN

1479-6694

E-ISSN

1744-8301

DOI

10.2217/fon-2017-0592

How to access this item